Novartis stocks have been undergoing considerable fluctuation. The bio-pharmaceutical company was recently downgraded to a 'Sell' by
Goldman Sachs, citing overvaluation and concerns about growth. Despite this, several organizations, including Goldman Sachs and Geneos Wealth Management, have acquired a significant number of Novartis shares. Integration Wealth Concepts, NewEdge Advisors, and Jones Financial Companies are among the firms that decrease their stake in the company.
Novartis is also making significant business moves, including the acquisition of
Tourmaline Bio for $1.4 billion which has induced a surge in its stock. Meanwhile, the company's Q2 reports indicate an earning and sales beat, and also the retirement of CFO.
Zacks Research maintains an optimistic outlook regarding Novartis' FY2027 earnings and consider it as a Top Value Stock for the long term. However, following the acquisition of Tourmaline Bio several outlets including Wedbush and Guggenheim have downgraded Tourmaline Bio's stock ratings.
Novartis Stocks News Analytics from Thu, 03 Apr 2025 07:00:00 GMT to Sat, 13 Sep 2025 23:37:12 GMT -
Rating -5
- Innovation 2
- Information 7
- Rumor -3
